## **Large scale genome-wide association analyses identify novel genetic loci and**

# **mechanisms in hypertrophic cardiomyopathy**

Rafik Tadros<sup>1,2,3\*</sub>
<sup>
"</sup>, Sean L Zheng<sup>4,5,6\*</sup>, Christopher Grace<sup>7,8</sup>, Paloma Jordà<sup>1,2</sup>, Catherine Francis<sup>4,6</sup>, Sean</sup> J Jurgens<sup>3,9</sup>, Kate L Thomson<sup>7,10</sup>, Andrew R Harper<sup>7,8</sup>, Elizabeth Ormondroyd<sup>7,8</sup>, Dominique M West<sup>7,8</sup>, Xiao Xu<sup>5</sup>, Pantazis I Theotokis<sup>4,5,6</sup>, Rachel J Buchan<sup>4,5,6</sup>, Kathryn A McGurk<sup>4,5</sup>, Francesco Mazzarotto<sup>4,11</sup>, Beatrice Boschi<sup>12</sup>, Elisabetta Pelo<sup>12</sup>, Michael Lee<sup>4</sup>, Michela Noseda<sup>4</sup>, Amanda Varnava<sup>4,13</sup>, Alexa MC Vermeer<sup>3,14,15</sup>, Roddy Walsh<sup>3</sup>, Ahmad S Amin<sup>3,15,16</sup>, Marjon A van Slegtenhorst<sup>17</sup>, Nicole Roslin<sup>18</sup>, Lisa J Strug<sup>19,20,21</sup>, Erika Salvi<sup>22</sup>, Chiara Lanzani<sup>23,24</sup>, Antonio de Marvao<sup>4,5</sup>, Hypergenes InterOmics Collaborators, Jason D Roberts<sup>25</sup>, Maxime Tremblay-Gravel<sup>1,2</sup>, Genevieve Giraldeau<sup>1,2</sup>, Julia Cadrin-Tourigny<sup>1,2</sup>, Philippe L L'Allier<sup>1,2</sup>, Patrick Garceau<sup>1,2</sup>, Mario Talajic<sup>1,2</sup>, Yigal M Pinto<sup>3,15,16</sup>, Harry Rakowski<sup>26</sup>, Antonis Pantazis<sup>6</sup>, John Baksi<sup>4,6</sup>, Brian P Halliday<sup>4,6</sup>, Sanjay K Prasad<sup>4,6</sup>, Paul JR Barton<sup>4,5,6</sup>, Declan P O'Regan<sup>5</sup>, Stuart A Cook<sup>5,27,28</sup>, Rudolf A de Boer<sup>29</sup>, Imke Christiaans<sup>30</sup>, Michelle Michels<sup>15,29</sup>, Christopher M Kramer<sup>31</sup>, Carolyn Y Ho<sup>32</sup>, Stefan Neubauer<sup>33</sup>, HCMR Investigators, Paul M Matthews<sup>34</sup>, Arthur A Wilde<sup>3,15,16,35</sup>, Jean-Claude Tardif<sup>1,2</sup>, Iacopo Olivotto<sup>36</sup>, Arnon Adler<sup>37,38</sup>, Anuj Goel<sup>7,8\*</sup>, James S Ware<sup>4,5,6,39\*</sup>, Connie R Bezzina<sup>3,15\*</sup>, Hugh Watkins<sup>7,8\*</sup>

\* These authors contributed equally to this work

# ✉ **Correspondence to**:

rafik.tadros@umontreal.ca j.ware@imperial.ac.uk c.r.bezzina@amsterdamumc.nl hugh.watkins@rdm.ox.ac.uk

## **Authors affiliations**

<sup>1</sup>Cardiovascular Genetics Centre, Montreal Heart Institute, Montreal, QC, Canada, <sup>2</sup>Faculty of Medicine, Université de Montréal, Montreal, QC, Canada, <sup>3</sup>Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, <sup>4</sup>National Heart & Lung Institute, Imperial College London, London, UK, <sup>5</sup>MRC London Institute of Medical Sciences, Imperial College London, London, UK, <sup>6</sup>Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK, <sup>7</sup>Radcliffe Department of Medicine, University of Oxford, Division of Cardiovascular Medicine, John Radcliffe Hospital, Oxford,

UK, <sup>8</sup>Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK, <sup>9</sup>Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA, <sup>10</sup>Oxford Genetics Laboratories, Churchill Hospital, Oxford, UK, 11Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>12</sup>Genetics Unit, Careggi University Hospital, Florence, Italy, <sup>13</sup>Imperial College Healthcare NHS Trust, Imperial College London, London, UK, <sup>14</sup>Department of Clinical Genetics, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, 15European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart, (ERN GUARD-HEART; https://guardheart.ern-net.eu), <sup>16</sup>Department of Clinical Cardiology, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, <sup>17</sup>Department of Clinical Genetics, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands, 18The Centre for Applied Genomics, Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada, 19Departments of Statistical Sciences and Computer Science, Data Sciences Institute, University of Toronto, Toronto, ON, Canada, <sup>20</sup>The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada, 21Ontario Regional Centre, Canadian Statistical Sciences Institute, University of Toronto, Toronto, ON, Canada, <sup>22</sup>Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, 23Genomics of Renal Diseases and Hypertension Unit, Nephrology Operative Unit, IRCCS San Raffaele Hospital, Milan, Italy, 24Chair of Nephrology, Vita-Salute San Raffaele University, Milan, Italy, <sup>25</sup>Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, ON, Canada, <sup>26</sup>Peter Munk Cardiac Centre, Toronto, ON, Canada, <sup>27</sup>National Heart Centre Singapore, Singapore, <sup>28</sup>Duke-National University of Singapore Medical School, Singapore, 29Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands, 30Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands, <sup>31</sup>Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA, 32Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA, 33Division of Cardiovascular Medicine, Radcliffe Department of Medicine, NIHR Oxford Health Biomedical Research Centre, University of Oxford, Oxford, UK, 34Department of Brain Sciences and UK Dementia Research Institute, Imperial College London, London, UK, <sup>35</sup>ECGen, Cardiogenetics Focus Group of EHRA, France, <sup>36</sup>Department of Experimental and Clinical Medicine, Meyer Children Hospital, University of Florence, Florence, Italy, 37Division of Cardiology, Peter Munk Cardiac Centre, University Health Network,

Toronto, ON, Canada, 38Department of Medicine, University of Toronto, Toronto, ON, Canada, <sup>39</sup> Program in Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Hypergenes InterOmics Collaborators: Daniele Cusi, Paolo Manunta, Lorena Citterio, Nicola Glorioso

HCMR Investigators: Theodore Abraham, Lisa Anderson, Evan Appelbaum, Camillo Autore, Colin Berry, Elena Biagini, William Bradlow, Chiara Bucciarelli-Ducci, Amedeo Chiribiri, Lubna Choudhury, Andrew Crean, Dana Dawson, Milind Desai, Patrice Desvigne-Nickens, Eleanor Elstein, Andrew Flett, Matthias Friedrich, Nancy Geller, Stephen Heitner, Adam Helms, Daniel Jacoby, Dong-Yun Kim, Han Kim, Bette Kim, Eric Larose, Masliza Mahmod, Heiko Mahrholdt, Martin Maron, Gerry McCann, Saidi Mohiddin, Francois-Pierre Mongeon, Sherif Nagueh, David Newby, Anjali Owens, Sven Plein, Ornella Rimoldi, Michael Salerno, Jeanette Schulz-Menger, Mark Sherrid, Albert van Rossum, Jonathan Weinsaft, James White, Eric Williamson.

 **Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality with both monogenic and polygenic components. We here report results from the largest HCM genome-wide association study (GWAS) and multi-trait analysis (MTAG) including 5,900 HCM cases, 68,359 controls, and 36,083 UK Biobank (UKB) participants with cardiac magnetic resonance (CMR) imaging. We identified a total of 70 loci (50 novel) associated with HCM, and 62 loci (32 novel) associated with relevant left ventricular (LV) structural or functional traits. Amongst the common variant HCM loci, we identify a novel HCM disease gene,** *SVIL***, which encodes the actin-binding protein supervillin, showing that rare truncating** *SVIL* **variants cause HCM. Mendelian randomization analyses support a causal role of increased LV contractility in both obstructive and non-obstructive forms of HCM, suggesting common disease mechanisms and anticipating shared response to therapy. Taken together, the findings significantly increase our understanding of the genetic basis and molecular mechanisms of HCM, with potential implications for disease** 

### **management.**

 HCM is a disease of cardiac muscle characterized by thickening of the LV wall with an increased risk of arrhythmia, heart failure, stroke and sudden death. Previously viewed as a Mendelian disease with 16 rare pathogenic variants in cardiac sarcomere genes identified in ~35% of cases (HCM<sub>SARC+</sub>), HCM is 17 now known to have complex and diverse genetic architectures.<sup>1</sup> Prior studies have established that common genetic variants underlie a large portion of disease heritability in HCM not caused by rare 19 pathogenic variants (HCM<sub>SARC</sub>) and partly explain the variable expressivity in HCM patients carrying 20 pathogenic variants (HCM<sub>SARC+</sub>), but such studies had limited power to identify a large number of 21 significant loci. $2,3$ 

 We report a new meta-analysis of 7 case-control HCM GWAS datasets, including 3 not previously published, comprising a total of 5,900 HCM cases, 68,359 controls and 9,492,702 variants with a minor allele frequency (MAF)>1% (**Supplementary Table 1**; Study flowchart in **Figure 1**). Using the 25 conventional genome-wide significance threshold ( $P < 5x10^{-8}$ ), 34 loci were significantly associated 26 with HCM, of which 15 were novel (Table 1). We then performed 2 stratified analyses in HCM<sub>SARC+</sub> 27 (1,776 cases) and HCM<sub>SARC</sub>. (3,860 cases), and identified an additional 1 locus and 4 loci, respectively 28 (Table 1; Supplementary Table 2; Supplementary Figure 1). Using conditional analysis<sup>4</sup>, we identified 29 additional suggestive and independent associations with HCM, HCM<sub>SARC+</sub>, and HCM<sub>SARC</sub>- with a false discovery rate (FDR) <1% (**Supplementary Table 3**). A locus on chromosome 11 which includes

31 *MYBPC3,* a well-established disease gene, is associated with HCM and HCMSARC+, but not HCMSARC-, implying that this association is tagging known founder pathogenic variants in *MYBPC3*. 32 2,3 We 33 estimated the heritability of HCM attributable to common genetic variation ( $h^2_{SNP}$ ) in the all-comer 34 analysis to be 0.17 $\pm$ 0.02 using LD score regression (LDSC)<sup>5</sup>, and, as expected, found higher estimates 35 (0.25±0.02) using genome-based restricted maximum likelihood (GREML)<sup>6</sup>, with higher  $h^2_{SNP}$  in 36 HCMSARC- (0.29±0.02) compared to HCMSARC+ (0.16±0.04) (**Supplementary Table 4**).

37 Rare variants in sarcomere genes that cause HCM and dilated cardiomyopathy (DCM) are known to  $38$  have opposing effects on contractility<sup>7</sup> and we previously demonstrated that HCM and DCM GWAS 39 loci similarly overlap, with opposite direction of effect.<sup>3</sup> We leveraged such opposing genomic effects 40 in HCM and DCM to identify additional loci involved in HCM. Bayesian pairwise analysis (GWAS-PW<sup>8</sup>) 41 including the present HCM GWAS meta-analysis and a published DCM GWAS<sup>9</sup> identified four genomic 42 regions where the same variant was deemed causal for both diseases with a posterior probability >0.9 43 (**Supplementary Table 5**). In all 4 genomic regions, opposing directional effects were observed in HCM 44 and DCM. The top mapped genes at these loci using OpenTargets<sup>10</sup> were *HSPB7, BAG3*, *CCT8* and *SVIL*. 15 The former 3 loci were associated with HCM at P<5x10<sup>-8</sup> while the locus mapped to *SVIL* did not reach 46 GWAS significance (P=4.4x10<sup>-6</sup> in HCM; P=2.9x10<sup>-5</sup> in DCM; **Figure 2A-B**) and required further evidence 47 to support implication in HCM. *SVIL* encodes supervillin, a large, multi-domain actin and myosin 48 binding protein with multiple muscle and non-muscle isoforms, of which the muscle isoform has 49 known roles in myofibril assembly and Z-disk attachment.<sup>11</sup> SVIL is highly expressed in cardiac, 50 skeletal, and smooth muscle myocytes in the Genotype Tissue Expression (GTEx) v9 single-nuclei RNA 51 sequencing (snRNA-seq) dataset<sup>12</sup>, and *SVIL* morpholino knockdown in zebrafish produces cardiac 52 abnormalities.<sup>13</sup> In humans, loss of function (LoF) *SVIL* variants have been associated with smaller 53 descending aortic diameter<sup>14</sup> and homozygous LoF *SVIL* variants have been shown to cause a skeletal 54 myopathy with mild cardiac features (left ventricular hypertrophy).<sup>15</sup> To provide further evidence 55 linking *SVIL* to human HCM and to explore the association of *SVIL* LoF variants with HCM, we 56 performed rare variant burden analysis including 1,845 clinically-diagnosed unrelated HCM cases and 57 37,481 controls. We demonstrate a 10.5-fold (95% CI: 4.1-26.8; P:2.3x10<sup>-7</sup>) excess burden of *SVIL* LoF 58 variants in HCM cases (**Figure 2C-D**; List of annotated variants in **Supplementary Table 6a**). Notably, 59 the excess burden is even greater at 15.3-fold (95% CI: 5.7-41.3; P:7x10<sup>-7</sup>) when restricting the 60 analysis to high confidence LoF variants affecting the predominant SVIL transcript in LV

(ENST00000375400) (**Supplementary Table 6b**). In one family, the *SVIL* LoF variant (p.(Gln255\*)) was

carried by two cousins with HCM (parents deceased), providing some evidence of co-segregation.

Taken together, these data support *SVIL* as a novel HCM disease gene.

 To further maximize locus discovery in HCM, we performed a multi-trait analysis of GWAS (MTAG<sup>16</sup>; **Figure 3**). We first completed a GWAS of 10 cardiomyopathy-relevant LV traits in 36,083 participants 66 of the UKB without cardiomyopathy and with available CMR, with machine learning assessment<sup>17</sup> of LV volumes, wall thickness (mean and maximal) and myocardial strain (**Supplementary Table 7**; **Supplementary Figures 2-11**). We discovered 62 loci associated with LV traits (32 novel), of which 30 showed association with HCM with nominal significance (P<0.001) and 13 were mapped to genes 70 associated with Mendelian heart disease (Supplementary Table 8). LDSC analyses<sup>18</sup> demonstrated high genetic correlations (rg) between LV traits within 3 clusters (contractility, volume and mass) and with HCM (**Figure 3**, **Supplementary Table 9**). Leveraging such correlations, we then performed MTAG with HCM and 3 LV traits including the most correlated trait with HCM from each cluster, namely global circumferential strain (contractility cluster; rg -0.62), LV end-systolic volume (volume cluster; rg -0.48), and the ratio of LV mass to end-diastolic volume (mass cluster; rg 0.63). MTAG resulted in a 76 significant increase in mean  $\chi^2$  equivalent to ~29% increase in effective sample size of the HCM GWAS 77 (from 21,725 to 28,106), with an estimated upper bound of the false discovery rate (maxFDR)<sup>16</sup> of 0.027. MTAG resulted in a substantial step up in loci discovered, identifying a total of 68 loci 79 associated with HCM at P<5x10 $^8$ , including 48 that have not been previously published (13 novel ones also identified in the single-trait HCM meta-analysis, and 35 were additionally novel by MTAG) (**Figure 4**, **Supplementary Table 10**). Two of the 34 loci reaching genome-wide significance in the HCM GWAS were not significant in MTAG (loci mapped to *TRDN*/*HEY2* and *CHPF*). The total number of loci identified in GWAS or MTAG is therefore 70, of which 50 have not been previously published. Notably, the locus mapped to *SVIL* which was uncovered from the GWAS-PW analysis reached genome-wide 85 significance in MTAG (P=1.1x10<sup>-8</sup>). Although it was not possible to test for replication for the 35 novel 86 MTAG loci, a prior study strongly supports the robustness of the HCM-LV traits MTAG approach.<sup>3</sup>

87 MAGMA<sup>19</sup> gene-set analysis identified multiple significant gene sets linked to muscle, contractility and sarcomeric function (**Supplementary Table 11**) and tissue expression analysis pointed to cardiac tissue (LV and atrial appendage, AA), and to a lower degree, other tissues with smooth muscle content, including arterial tissues (**Supplementary Table 12**). Within cardiac tissue, we further

91 explored the contribution of specific cell types in HCM by leveraging available snRNA-seq data from 92 donor human hearts.<sup>20</sup> Using sc-linker<sup>21</sup>, we identified significant enrichment of heritability in 93 cardiomyocyte and adipocyte cell types (cardiomyocyte: FDR-adjusted P=1.8x10<sup>-6</sup>; adipocyte: FDR-94 adjusted P=3.0x10<sup>-3</sup>) and state gene programs (**Supplementary Figure 12**).

95 Prioritization of potential causal genes in HCM MTAG loci was performed using OpenTargets variant 96 to gene (V2G) mapping<sup>10</sup> (**Supplementary Table 13**) and FUMA<sup>22</sup> (**Supplementary Table 14**). Of all 97 prioritized genes, 26 were selected based on concordance in both OpenTargets (top 3 genes per 98 locus) and FUMA, as well as LV specific expression in bulk RNAseq data (GTEx v8) and expression in 99 cardiomyocytes using publicly available snRNA-seq data from a recent study<sup>23</sup> (**Supplementary Figure** 100 **13** and **Supplementary Tables 13-14**). Of those, 7 are known Mendelian cardiomyopathy genes (*PLN, FLNC, FHOD3* and *ALPK3* were previously reported<sup>2,3</sup>, while *ACTN2, TTN* and *NEXN* are in novel 102 common variant HCM loci). Among the other 19 predominantly LV-expressed genes, 5 are mapped to 103 previously published known HCM loci, while 14 are in novel loci and include genes involved in 104 cardiomyocyte energetics and metabolism (*RNF207<sup>24</sup>, MLIP*<sup>25</sup>), myocyte differentiation and 105 transcriptional regulation (*MITF*<sup>26</sup>, *PROX1*<sup>27</sup>, *TMEM182*<sup>28</sup>), myofibril assembly (*SVIL*<sup>11</sup>), and calcium handling and contractility (*PDE3A*29, *SRL*<sup>30</sup> 106 ). Last, a transcriptome-wide association study (TWAS) with 107 S-MultiXcan<sup>31</sup> using the MTAG summary statistics with cardiac tissues (LV and AA) from GTEx V8 108 identified 127 genes significantly associated with HCM at P<3.7x10<sup>-6</sup> (**Supplementary Table 15**). Of 109 those, 50 were not mapped to MTAG loci using either FUMA or OpenTargets, including *HHATL*  $110$  (P=1x10<sup>-11</sup>), a gene of uncertain function prioritized based on dominant LV expression, and whose 111 depletion in zebrafish may lead to cardiac hypertrophy. $32$ 

112 Rare sarcomeric variants associated with HCM have been shown to result in increased contractility, 113 and cardiac myosin-inhibitors attenuate the development of sarcomeric HCM in animal models.<sup>33</sup> 114 Prior data from GWAS and Mendelian randomization (MR) also support a causal association of 115 increased LV contractility with HCM, extending beyond rare sarcomeric variants.<sup>3</sup> Pharmacologic 116 modulation of LV contractility using myosin inhibitors has recently been approved in the treatment of 117 HCM associated with LV obstruction (oHCM)<sup>34,35</sup>, but remains of uncertain utility in non-obstructive 118 HCM (nHCM) which represents a significant proportion of the HCM patient population (both HCM<sub>SARC-</sub> 119 and HCM<sub>SARC+</sub>) and where no specific therapy currently exists. To further dissect the specific 120 implication of LV contractility in nHCM and oHCM, we performed two-sample MR, testing the causal

 association of LV contractility as exposure, with HCM, nHCM and oHCM as outcomes. LV contractility was assessed with CMR using a volumetric method (LV ejection fraction, LVEF), and tridimensional 123 tissue deformation methods (i.e. global LV strain in the longitudinal (strain<sup>long</sup>), circumferential 124 (straincirc) and radial (strain<sup>rad</sup>) directions). Results from the primary MR inverse variance weighted (IVW) analysis are shown in **Figure 5A** and sensitivity analyses results appear in **Supplementary Table 16** and **Supplementary Figures 14-15**. Although significant heterogeneity in the exposure–outcome effects are limitations, MR findings support a causal association between increased LV contractility and increased risk for both nHCM and oHCM, with a substantial risk increase of 12-fold and 29-fold 129 per standard deviation increase in strain<sup>circ</sup>, respectively (Figure 5A). Altogether, these data suggest that increased contractility is involved in both oHCM and nHCM development, and thus myosin inhibitors currently approved for symptom control in oHCM may also be of clinical benefit in nHCM. Last, we also performed MR analyses exploring whether increased systolic (SBP) and diastolic (DBP) blood pressure, and pulse pressure (PP=SBP-DBP) are causally associated with nHCM and oHCM. As 134 for LV contractility, the causal association of SBP and DBP with HCM<sup>2</sup> extended to both oHCM and nHCM subgroups (**Figure 5B**, **Supplementary Table 16** and **Supplementary Figure 16**), suggesting that lowering blood pressure may be a therapeutic target to mitigate disease progression for both nHCM and oHCM.

 In conclusion, the large number of new susceptibility loci arising from this work support new inferences regarding disease mechanisms in HCM. With the identification of the role of *SVIL*, we have uncovered further evidence that a subset of genes underlies both monogenic and polygenic forms of 141 the condition. However, this shared genetic architecture does not extend to the core sarcomere 142 genes which cause monogenic HCM; instead, the common variant loci implicate processes outside the myofilament, thereby widening our biological understanding and pointing to the importance of downstream remodeling pathways. These insights have therapeutic implications. The shared mechanistic pathways between obstructive and non-obstructive forms of HCM suggest that the new class of myosin inhibitors may be effective in both settings, while the further exploration of newly 147 implicated loci and pathways may in the future yield new treatment targets.



**Figure 1: Study Flowchart.** Abbreviations: DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LV, left ventricular; maxFDR, upper bound of the estimated false discovery rate computed using MTAG; MRI, magnetic resonance imaging;  $N_{\text{eff}}$ , effective sample size (see methods); UKB, UK Biobank.



**Figure 2: GWAS and rare variant association analyses identify** *SVIL* **as a novel HCM gene. A**) GWAS in HCM and DCM9 identify a subthreshold locus near *SVIL*. GWAS-PW analysis identifies this locus as sharing the same causal variant (model 3) in both DCM and HCM (posterior probability of model 3, PPA3, 0.98). **B**) Summary statistics of the lead HCM variant (rs6481586) showing effect and non-effect alleles (EA/NEA) and opposite directions of effect (regression coefficient) in HCM and DCM. **C**) Forest plot showing excess of rare loss of function (LoF) variants in *SVIL* in HCM vs. controls in the Rare Disease Bioresource (BRRD), Genomics England (GeL) and Oxford laboratory. **D**) Schematic of the rare LoF *SVIL* variants in HCM cases (top, total N=1,845) and controls (bottom, total N=37,481) along the linear structure of SVIL. The coordinates reflect the codon numbers, and the coloured bars are the exons. The height of the exons reflects expression in cardiac isoforms and is not to scale. Detailed variant annotation appears in Supplementary Table 6.



**Figure 3: LV traits and HCM genetic correlations and use of MTAG to empower locus discovery.**  Pairwise genetic correlation between left ventricular (LV) traits shown in heatmap as absolute values  $(|rg_{LV}|)$  ranging from 0 (white) to 1 (red). LV traits are sorted based on  $|rg_{LV}|$  along the x and y axes using Euclidean distance and complete hierarchical clustering into 3 clusters: LV contractility (blue), volume (green) and mass (dark red). See dendrogram on top. The table in the middle shows the individual LV trait common variant heritability ( $h^2$ <sub>SNP</sub>) and genetic correlation with HCM (rg<sub>HCM</sub>), with corresponding standard errors (SE). The trait with the strongest correlation (based on  $r_{HICM}$ ) in each of the 3 clusters was carried forward for multi-trait analysis of GWAS (MTAG) to empower locus discovery in HCM. MTAG resulted in an increase of the effective sample size (N<sub>eff</sub>, based on number of cases and controls and increase in mean  $\chi^2$  statistic) from 21,816 to 28,224, with an estimated upper bound of the false discovery rate (maxFDR) of 0.027. Other abbreviations: LVconc, LV concentricity index (LVM/LVEDV); LVEDVi, LV end-diastolic volume indexed for body surface area; LVEF, LV ejection fraction; LVESVi, LV end-systolic volume indexed for body surface area; LVMi, LV mass indexed for body surface area; maxWT, maximal LV wall thickness; meanWT, mean LV wall thickness; strain<sup>circ</sup>, global LV circumferential strain; strain<sup>long</sup>, global LV longitudinal strain; strain<sup>rad</sup>, global LV radial strain. Note: Since strain<sup>circ</sup> and strain<sup>long</sup> are negative values where increasingly negative values reflect increased contractility, we show -strain<sup>circ</sup> and -strain<sup>long</sup> to facilitate interpretation rg<sub>HCM</sub> sign. Full rg<sub>LV</sub> and rg $H_{\text{HCM}}$  results are shown in Supplementary Table 9.



**Figure 4: Circular Manhattan plot of HCM summary statistics from MTAG analysis.** Previously published loci are identified in black (N=20), novel loci discovered by single trait all-comer GWAS meta-analysis are identified in blue (N=13) and additional novel loci from MTAG are identified in green (N=35). Two other loci reaching GWAS significance threshold in the single trait HCM GWAS meta-analysis but not reaching significance in MTAG are not shown (mapped to *TRDN*/*HEY2* and *CHPF*, see Table 1). Results with P<1x10<sup>-15</sup> are assigned P=1x10<sup>-15</sup>. Variants with P<5x10<sup>-8</sup> are shown as black triangles. Locus naming was performed primarily by OpenTargets gene prioritisation considering FUMA and prior gene association with Mendelian HCM. See Supplementary Table 10 for loci details.



**Figure 5: Mendelian randomization (MR) analysis of LV contractility and blood pressure on risk of obstructive (oHCM) and non-obstructive (nHCM) hypertrophic cardiomyopathy (HCM).** Odds ratio (OR) represented are those inferred from the inverse variance weighted (IVW) two-sample MR per standard deviation increase (SD). The error bars represent the 95% confidence interval of the OR. **A)** MR suggests causal association of LV contractility (exposure) with HCM, oHCM and nHCM (outcomes), where increased contractility increases disease risk. Genetic instruments for LV contractility were selected from the present GWAS of left ventricular ejection fraction (LVEF), and strain in the radial (stain\_rad), longitudinal (stain\_long) and circumferential (strain\_circ) directions in 36,083 participants of the UKB without cardiomyopathy and with available CMR. To facilitate interpretation of effect directions, OR for strain circ and strain long reflect those of increased contractility (more negative strain circ and strain long values). The outcome HCM GWAS included 5,927 HCM cases vs. 68,359 controls. Of those, 964 cases and 27,163 controls were included in the oHCM GWAS, and 2,491 cases and 27,109 were included in the nHCM GWAS. Note a logarithmic scale in the x-axis. **B)** MR suggests causal associations of systolic (SBP) and diastolic (DBP) blood pressure with HCM, nHCM and oHCM. Genetic instruments for SBP, DBP and pulse pressure (PP = SBP-DBP) were selected from a published GWAS including up to 801,644 individuals.<sup>36</sup> See Supplementary Table 16 for full MR results.

#### **Table 1: Lead variants from the HCM meta-analysis.**



All reported summary statistics refer to the all HCM case-control meta-analysis results, including for loci identified only in the sarcomere-positive and -negative stratified analyses (HCM<sub>SARC+</sub> and HCM<sub>SARC-</sub>). Table sorted increasing order of the all-comer p-value. Novel loci are shown in **bold**. Locus naming was performed primarily by OpenTargets<sup>10</sup> gene mapping, also considering FUMA<sup>22</sup> mapping and prior rare variant associations with HCM. <sup>37</sup> **Abbreviations**: EA/NEA, effect and non-effect alleles; EAF, effect allele frequency; GRCh37, genomic coordinates using the Genome Reference Consortium Human Build 37; GWS, genome-wide significant (P≤5x10<sup>-8</sup>); OR (95% CI), odds ratio with 95% confidence interval.

#### **Methods**

#### GWAS of hypertrophic cardiomyopathy

 The HCM GWAS included HCM cases and controls from 7 strata: the Hypertrophic Cardiomyopathy Registry (HCMR), a Canadian HCM cohort, a Netherlands HCM cohort, the Genomics England 100K Genome Project (GEL), the Royal Brompton HCM cohort, an Italian HCM cohort and the BioResource for Rare Disease (BRRD) project. Quality control (QC) and association analyses were performed per strata, followed by a meta-analysis. The 7 strata are described in the **Supplementary Note** and in **Supplementary Table 1**. Cases consisted of unrelated patients diagnosed with HCM in presence of unexplained left ventricular (LV) hypertrophy defined as a LV wall thickness (LVWT) >15mm, or >13mm and either presence of family history of HCM or a pathogenic or likely pathogenic genetic variant causing HCM. HCM cases underwent gene panel sequencing as per clinical indications. Variants identified within 8 core sarcomere genes (*MYBPC3*, *MYH7*, *TNNI3*, *TNNT2*, *MYL2*, *MYL3*, *ACTC1* and *TPM1*) were centrally assessed at the Oxford laboratory using the American College of 14 Medical Genetics and Genomics (ACMG) guidelines.<sup>38</sup> HCM cases were dichotomised into sarcomere- positive and sarcomere-negative groups using a classification framework previously reported in 16 Neubauer et al.<sup>39</sup> In addition to the primary all-comer GWAS analyses including all cases with HCM (total of 5,900 cases and 68,359 controls), analyses stratified for sarcomere status in cases and randomly allocated controls were performed, including a total of 1,776 cases vs. 29,414 controls in 19 the sarcomere-positive analysis (HCM<sub>SARC+</sub>) and 3,860 cases vs. 38,942 controls in the sarcomere-negative analysis (HCM<sub>SARC</sub>).

 Meta-analyses for the all-comer HCM GWAS was performed on betas and standard errors using 22 GWAMA.<sup>40</sup> We kept variants where meta-analysis came from 2 or more studies and also had a sample 23 size >5,000. Genomic inflation was estimated from the median  $\chi^2$  distribution and using HapMap3 24 European ancestry LD scores using LD Score Regression.<sup>5</sup> All variants were mapped to Genome Reference Consortium Human Build 37 (GRCh37) extrapolated using the 1000 Genome phase 3 26 genetic maps. A genome wide significant locus was assigned where two variants had a meta-analysis 27 P<5x10<sup>-8</sup> and were 0.5 cM distance apart. A similar approach was implemented for the HCM<sub>SARC+</sub> and 28 HCM<sub>SARC</sub>- stratified analyses which comprised 5 and 7 strata, respectively (the GEL and BRRD strata did not include enough sarcomere-positive HCM cases). Variants were retained where meta-analysis came from 2 or more studies and had sample size >5,000 for sarcomere-negative and >2,500 for

31 sarcomere-positive. The final dataset included 9,492,702 (all comer), 7,614,734 (HCM<sub>SARC+</sub>) and

32 9,226,079 (HCM<sub>SARC-</sub>) variants after filtering. The results of the all-comer HCM GWAS meta-analysis

33 and stratified analyses are presented in **Table 1**, **Supplementary Figure 1** and **Supplementary Table 2**.

34 A false discovery rate (FDR) 1% P value cut-off was derived from the all-comer, HCM<sub>SARC+</sub> and HCM<sub>SARC-</sub>

35 summary statistics using Simes method (Stata 10.1) and the corresponding P-values were 8.5x10<sup>-6</sup>,

 $36$  1.6x10<sup>-6</sup> and 7.8x10<sup>-6</sup> respectively. Using the 1% FDR P value thresholds, we then performed a

37 stepwise model selection to identify 1% FDR independently associated variants using GCTA.<sup>4</sup> The

38 analysis was performed chromosome wise using default window of 10Mbp, 0.9 collinearity and UKB

39 reference panel containing 60K unrelated European ancestry participants. The results of this

40 conditional analysis are presented in **Supplementary Table 3**.

## 41 HCM heritability attributable to common variants

42 We estimated the heritability of HCM attributable to common genetic variation  $(h^2_{SNP})$  in the all-

43 comer HCM, as well as HCM<sub>SARC+</sub> and HCM<sub>SARC</sub> using LD score regression (LDSC)<sup>5</sup> and genome-based

44 restricted maximum likelihood (GREML)<sup>6</sup>. For LDSC, HapMap3 SNPs were selected from the summary

45 statistics corresponding to HCM, HCM<sub>SARC+</sub> and HCM<sub>SARC</sub> meta-analyses. The  $h^2$ <sub>SNP</sub> was computed on

46 the liability scale assuming a disease prevalence of 0.002.<sup>41</sup> Since LDSC tends to underestimate  $h^2$ <sub>SNP</sub>,

47 we also estimated  $h^2$ <sub>SNP</sub> using GREML, as previously performed.<sup>2,3</sup> We first computed  $h^2$ <sub>SNP</sub> for HCM,

48 HCM<sub>SARC+</sub> and HCM<sub>SARC</sub>, using GREML for each of the largest 3 strata (HCMR, the Canadian HCM cohort

49 and the Netherlands HCM cohort), followed by fixed-effects and random-effects meta-analyses

50 combining all 3 strata. To exclude the contribution of rare founder HCM causing variants, we excluded

51 the *MYBPC3* locus for the Canadian and Netherlands strata and the *TNNT2* locus for the Canadian

52 stratum.<sup>3</sup> The results of  $h^2$ <sub>SNP</sub> analyses are presented in **Supplementary Table 4**.

## 53 Locus colocalization in dilated (DCM) and hypertrophic cardiomyopathy (HCM)

54 We explored colocalization of HCM and DCM loci using GWAS-PW.<sup>8</sup> The genome was split into 1,754 approximately independent regions and the all-comer HCM meta-analysis results were analysed with 56 those of a publicly available DCM GWAS<sup>9</sup> using a Bayesian approach. GWAS-PW fits each locus into one of the 4 models where model 1 is association in only the first trait, model 2 is association in only the second trait, model 3 when the two traits co-localize and model 4 when the genetic signals are independent in the two traits. We considered a locus to show colocalization when either trait

60 harbours a genetic signal with  $P<1x10^{-5}$  and the GWAS-PW analysis demonstrates a posterior

probability of association for model 3 (PPA3) greater than 0.8. Results of GWAS-PW are presented in

**Supplementary Table 5** and **Figure 2** (panels **A** and **B**, for the *SVIL* locus).

#### Association of rare *SVIL* loss of function (LoF) variants with HCM

64 We assessed the association of LoF variants in *SVIL* with HCM in 3 cohorts (BRRD<sup>42</sup>, GEL<sup>43</sup> and the Oxford laboratory) followed by a meta-analysis. For BRRD, HCM cases were probands within the bio- resource project HCM. Controls were all remaining individuals within the BRRD projects except for those within the GEL and GEL2 projects (the Genomics England pilot data), since there is overlap of individuals with the GEL analysis in these two projects. For GEL, HCM cases were probands with a primary disease of HCM. Controls were probands without any primary or secondary cardiovascular disease and without any primary and secondary congenital myopathy, since *SVIL* has previously been 71 associated with myopathy.<sup>15</sup> For the Oxford laboratory, cases were clinically diagnosed with HCM and referred for diagnostic panel testing. The control group for the Oxford analysis consisted of 5,000 individuals randomly selected from the UK Biobank (UKB), which were all white British and unrelated. They had normal LV volume and function and no clinical diagnosis of cardiomyopathy (HCM or DCM). Genetic variants were identified using next generation sequencing (whole-genome sequencing for BRRD and GEL, panel/exome sequencing for Oxford cases and UKB controls) and annotated using the 77 Ensembl variant effect predictor (VEP).<sup>44</sup> LoF variants in *SVIL* were defined as those with the following VEP terms: stop lost, stop gained, splice donor variant, splice acceptor variant and frameshift variant. 79 Only variants with a MAF<10 in the non-Finish European ancestral group of gnomAD v2.1.1 $45$  were 80 selected. Only LoF variants present in the Matched Annotation from NCBI and EMBL-EBI (MANE) / 81 canonical transcript (NM\_021738.3; ENST00000355867.9) were retained for the analysis. The proportion of cases and controls with *SVIL* LoF variants were compared using the Fisher Exact test for each of the 3 case-control datasets, followed by a fixed-effect model meta-analysis. We also performed a secondary analysis where association of *SVIL* LoF variants with HCM was restricted to variants that cause LoF in the primary LV transcript (ENST00000375400), and excluding variants expected to escape nonsense-mediated decay. The results of *SVIL* LoF variant association with HCM are shown in **Figure 2C**, and the list of *SVIL* LoF variants identified in cases and controls is shown in **Figure 2D** with annotation in **Supplementary Table 6a**. Results of the secondary analysis restricted to high confidence LoF variants are shown in **Supplementary Table 6b**.

#### GWAS of cardiac magnetic resonance-derived left ventricular traits

 *UK Biobank (UKB) study population*. The UKB is an open-access population cohort resource that has recruited half a million participants in its initial recruitment phase, from 2006-2010. At the time of analysis, CMR imaging data was available from 39,559 individuals in the imaging substudy. The UKB 94 CMR acquisition protocol has been described previously.<sup>46</sup> In brief, images were acquired according to a basic cardiac imaging protocol using clinical 1.5 Tesla wide bore scanners (MAGNETOM Aera, Syngo Platform VD13A, Siemens Healthcare, Erlangen, Germany) in three separate imaging centers. Extensive clinical and questionnaire data and genotypes are available for these individuals. Clinical data were obtained at the time of the imaging visit. These included sex (31), age (21003), weight (21002), height (50), SBP (4080), DBP (4079), self-reported non-cancer illness code (20002), and ICD10 100 codes (41270). The mean age at the time of CMR was  $63 \pm 8$  (range 45-80), and 46% of participants were male. Cohort anthropometrics, demographics and comorbidities are reported in **Supplementary Table 7**. Exclusion criteria for the UKB imaging substudy included childhood disease, pregnancy and contraindications to MRI scanning. For the current analysis, we also excluded, by ICD-10 code and/or self-reported diagnoses, any subjects with heart failure, cardiomyopathy, a previous myocardial infarction, or structural heart disease. After imaging quality control and exclusions for comorbidities or genotype quality control, we had a maximum cohort size of 36,083 individuals. The UKB received National Research Ethics Approval (REC reference 11/NW/0382). The present study was conducted under terms of UKB access approval 18545.

*LV trait phenotyping*. Description of CMR image analysis has previously been published<sup>3</sup> and is

detailed in the **Supplementary Note**. We included ten LV phenotypes for GWAS analyses: end-

diastolic volume (LVEDV), end-systolic volume (LVESV), ejection fraction (LVEF), mass (LVM),

concentricity index (LVconc = LVM/LVEDV), mean wall thickness (meanWT), maximum wall thickness

113 (maxWT) as well as global peak strain in radial (strain<sup>rad</sup>), longitudinal (strain<sup>long</sup>) and circumferential

(strain<sup>circ</sup>) directions. The means and standard deviations of all ten LV phenotypes, overall and

stratified by sex, are shown in **Supplementary Table 7**.

*LV trait genome-wide association analyses.* A description of genotyping, imputation and QC appears in

117 the **Supplementary Note**. The GWAS model for LVEF, LVconc, meanWT, maxWT, strain<sup>rad</sup>, strain<sup>long</sup>

118 and strain<sup>circ</sup> included age, sex, mean arterial pressure (MAP), body surface area (BSA, derived from

the Mosteller formula) and the first eight genotypic principal components as covariates. LVEDV,

 LVESV and LVM were indexed to body surface area for the analysis, as commonly performed in clinical practice. For indexed values (LVEDVi, LVESVi, LVMi), the GWAS model did not include BSA as a covariate, but all other covariates were the same as for non-indexed phenotypes. BOLT-LMM  $(123 \text{ (v2.3.2)}^{47}$  was used to construct mixed models for association with around 9.5 million directly genotyped and imputed SNPs. A high-quality set of directly genotyped model SNPs was selected to 125 account for random effects in the genetic association analyses. These were selected by MAF (>0.001), 126 and LD-pruned  $(r^2 < 0.8)$  to create an optimum SNP set size of around 500,000. The model was then applied to the > 9.8 million imputed SNPs passing quality control and filtering. Results of the LV traits GWAS are shown in **Supplementary Table 8** and **Supplementary Figures 2-11**.

 *Locus definition and annotation*. Genomic loci associated with all LV traits were annotated jointly. Specifically, summary statistics were combined and a P value corresponding to the minimal P value (minP) across all 10 summary statistics. The minP summary statics was then used to define loci using 132 FUMA v1.4.2<sup>22</sup> using a maximum lead SNP P-value of  $5x10^{-8}$ , maximum GWAS P-value of 0.05 and  $r^2$  threshold for independent significant SNPs of 0.05 (using the European 1000 Genomes Project dataset), and merging LD blocks within 250kb. Loci were then mapped to genes using positional mapping (<10kb), eQTL mapping using GTEx v8 restricted to atrial appendage, left ventricle and skeletal muscle tissues, and chromatin interaction mapping using left and right ventricles. See FUMA tutorial for detailed methods. Genes mapped using FUMA were further prioritized by querying the 138 Clinical Genomes Resource (ClinGen)<sup>48</sup> for genes linked to Mendelian heart disease with moderate, 139 strong or definitive evidence, and using a recent review of overlapping GWAS and Mendelian 140 cardiomyopathy genes.<sup>37</sup> In addition to FUMA locus to gene mapping, we also report closest gene and 141 top gene mapped using OpenTargets.<sup>10</sup> Annotated LV trait loci are shown in **Supplementary Table 8**.

#### Genetic correlations between HCM and LV traits

143 Pairwise genetic correlations for HCM and the 10 LV traits were assessed using LD score regression 144 (LDSC, v.1.0.1).<sup>18</sup> The analysis was restricted to well-imputed non-ambiguous HapMap3 SNPs, excluding SNPs with MAF<0.01 and those with low sample size, using default parameters. We then assessed genetic correlations for each of the 55 pairs (HCM and 10 LV traits) using precomputed LD scores from the European 1000 Genomes Project dataset. We did not constrain the single-trait and cross-trait LD score regression intercepts. The results of the genetic correlation analyses are shown in **Figure 3** and **Supplementary Table 9**.

#### 150 Multitrait analysis of GWAS (MTAG)

151 We performed multi-trait analysis of GWAS summary statistics using MTAG (v.1.0.8)<sup>16</sup> to increase power for discovery of genetic loci associated with HCM. MTAG jointly analyzes multiple sets of GWAS summary statistics of genetically correlated traits to enhance statistical power. Due to high computation needs to calculate the maximum false discovery rate (maxFDR) with MTAG, we limited the number of GWAS summary statistics to 4 (HCM + 3 LV traits). The 3 LV traits to include were selected as follows. First, we performed hierarchical clustering of the 10 LV traits using the absolute value of the pairwise genetic correlations, Euclidean distance and the complete method, predefining the number of clusters to 3. This resulted in clustering of LV traits into a LV contractility cluster (LVEF, 159 strainr<sup>ad</sup>, strain<sup>long</sup> and strain<sup>circ</sup>), a LV volume cluster (LVEDVi, LVESVi) and a LV mass cluster (LVMi, LVconc, meanWT, maxWT) (**Figure 3**). We then selected the trait with the highest genetic correlation 161 with HCM for each cluster (strain<sup>circ</sup>, LVESVi and LVconc) to include in MTAG together with HCM. Only SNPs included in all meta-analyses (that is HCM and LV traits) were used in MTAG. The coded/noncoded alleles were aligned for all 4 studies before MTAG, and multi-allelic SNPs were removed. All summary statistics refer to the positive strand of GRCh37 and, as such, ambiguous/palindromic SNPs (having alleles A/T or C/G) were not excluded. Regression coefficients (beta) and their standard errors were used as inputs for MTAG. The maxFDR was calculated as 167 suggested by the MTAG developers.<sup>16</sup> MaxFDR calculates the type I error in the analyzed dataset for 168 the worst-case scenario. We estimated the gain in statistical power by the increment in the effective 169 sample size (N<sub>eff</sub>). The N<sub>eff</sub> for the HCM GWAS was calculated using the following formula.<sup>16,49</sup>

$$
N_{eff(GWAS)} = \frac{4}{N cases^{-1} + Ncontrols^{-1}}
$$

171 The N<sub>eff</sub> for the HCM MTAG was estimated by means of the fold-increase in mean  $\chi^2$ , using the 172 following formula. $16$ 

173 
$$
N_{eff(MTAG)} = N_{eff(GWAS)} \times \left(\frac{\chi^2_{MTAG,mean} - 1}{\chi^2_{GWAS,mean} - 1}\right)
$$

174 The MTAG N<sub>eff</sub> corresponds to the approximate the sample size needed to achieve the same mean  $\chi^2$ 175 value in a standard GWAS. The results of HCM MTAG are presented in **Figure 4** and **Supplementary**  176 **Table 10**.

#### 178 Genome-wide annotation

- 179 Genome-wide analyses following MTAG were performed using MAGMA v.1.08, as implemented in
- 180 FUMA<sup>22</sup>, including gene-set and tissue expression analyses. We used Gene Ontology (GO) gene sets
- 181 from the Molecular Signatures Database (MSigDB, v.6.2) for the gene-set analysis and the Genotype-
- 182 Tissue Expression project (GTEx, v.8) for the tissue specificity analysis. The results of MAGMA analyses
- 183 are shown in **Supplementary Table 11** (gene-set analyses) and **Supplementary Table 12** (tissue
- 184 specificity analyses).
- 185 Cardiac cell type heritability enrichment analysis

186 Gene programs derived from single nuclei RNA sequencing (snRNA-seq) were used to investigate 187 heritability enrichment in cardiac cell types and states using the sc-linker framework.<sup>21</sup> This approach 188 uses snRNA-seq data to generate gene programs that characterize individual cell types and states. 189 These programs are then linked to genomic regions and the SNPs that regulate them by incorporating 190 Roadmap Enhancer-Gene Linking<sup>50,51</sup> and Activity-by-Contact models<sup>52,53</sup>. Finally, the disease 191 informativeness of resulting SNP annotations is tested using stratified LD score regression (S-LDSC)<sup>54</sup> 192 conditional on broad sets of annotations from the baseline-LD model.<sup>55,56</sup> Cell type and state-specific 193 gene programs were generated from snRNA-seq data of ventricular tissue from 12 control subjects, 194 with cell type and state annotations made as part of a larger study of ~880,000 nuclei (samples from 195 61 DCM and 12 control subjects.<sup>20</sup> Cell states that may not represent true biological states (for 196 example, technical doublets) were excluded from analysis. Results of sc-linker cardiac cell type 197 heritability enrichment analysis are shown in **Supplementary Figure 12**.

### 198 Locus to gene annotation

199 A genome wide significant HCM MTAG loci was assigned where two variants had a MTAG P<5x10<sup>-8</sup> 200 and were 0.5 cM distance apart, as performed for the HCM GWAS. Prioritization of potential causal 201 genes in HCM MTAG loci was performed using OpenTargets variant to gene (V2G) mapping<sup>10</sup> and 202 FUMA<sup>22</sup>. The lead SNP at each independent locus was used as input for OpenTargets V2G using the 203 release of October  $12^{th}$ , 2022. Locus to gene mapping with FUMA v1.3.7 was performed based on 1) 204 position (within 100kb), 2) eQTL associations in disease-relevant tissues (GTEx V8 left ventricle, atrial 205 appendage and skeletal muscle) and 3) chromatin interactions in cardiac tissue (left ventricle and 206 right ventricle, FDR  $P < 10^{-6}$ ).

 We further annotated genes mapped using OpenTargets and/or FUMA with their implication in 208 mendelian cardiomyopathy. Specifically, we queried the Clinical Genome Resource (ClinGen<sup>48,57</sup>) for genes associated with any cardiomyopathy phenotype with a level of evidence of moderate, strong or definitive and included genes with robust recent data supporting an association with Mendelian 211  $cardiomy$ 

212 We also prioritized genes based on RNA expression data from bulk tissue RNAseq data in the GTE $x^{58}$ 213 v8 dataset accessible at the GTEx portal and snRNA-seq data from Chaffin et al<sup>23</sup> accessible through the Broad Institute single cell portal (singlecell.broadinstitute.org). Using the GTEx v8 data, we assessed specificity of LV expression by computing the ratio of median LV transcripts per million (TPM) to the median TPM in other tissues excluding atrial appendage and skeletal muscle and averaging tissue within types (e.g., all arterial tissues, all brain tissues, etc.). High and Mid LV expression specificity were empirically defined as >10-fold and >1.5-fold LV to other tissues median 219 TPM ratios, respectively. Using snRNA-seq data from Chaffin et al<sup>23</sup>, we report the expression in the 220 cardiomyocyte 1 cell type using scaled mean expression (relative to each gene's expression across all cell types) and percentage of cells expressing. High and Mid expression in cardiomyocytes were empirically defined as percentage expressing cells ≥80% and 40-80%, respectively. Prioritized genes were defined as genes mapped using both OpenTargets (top 3 genes) and FUMA, AND had either 1) High LV specific expression, OR 2) High cardiomyocyte expression, OR 3) both Mid LV specific expression and Mid cardiomyocyte expression.

Gene mapping data including ClinGen cardiomyopathy genes at HCM loci, LV expression specificity

and cardiomyocyte expression are shown in **Supplementary Table 13** (OpenTargets genes) and

**Supplementary Table 14** (FUMA genes). Prioritized genes are illustrated in **Supplementary Figure 13**.

## Transcriptome-wide association study (TWAS)

 We used MetaXcan to test the association between genetically predicted-gene expression and HCM 231 using summary results from MTAG analysis.<sup>31,59</sup> Biologically-informed MASHR-based prediction 232 models of gene expression for left ventricle (LV) and atrial appendage (AA) tissue from GTEx v8<sup>60</sup> were 233 analysed individually with S-PrediXcan<sup>59</sup>, and then analysed together using S-MultiXcan.<sup>31</sup> GWAS MTAG summary statistics were harmonised and imputed to match GTEx v8 reference variants present 235 in the prediction model. To account for multiple testing, TWAS significance was adjusted for the total

236 number of genes present in S-MultiXcan analysis (13,558 genes,  $P=3.7x10^{-6}$ ). TWAS results are shown

## in **Supplementary Table 15**.

#### Two-sample Mendelian randomization (MR)

 We assessed whether increased contractility and blood pressure are causally linked to increased risk 240 of HCM globally and its obstructive (oHCM) and non-obstructive (nHCM) forms using two-sample MR. LV contractility and blood pressure parameters were used as exposure variables, and HCM, oHCM and 242 nHCM as outcomes. Analyses were performed using the TwoSampleMR (MRbase) package<sup>61</sup> (v.0.5.6) in R (v.4.2.0). Four exposure variables corresponding to measures of LV contractility were used 244 separately: LVEF as a volumetric marker of contractility, and global strain (strain<sup>circ</sup>, strain<sup>rad</sup> and 245 strain<sup>long</sup>) as contractility markers based on myocardial tissue deformation. Instrument SNPs for 246 contractility were selected based on the LV trait GWAS presented here using a P value threshold of  $\leq$  <5x10<sup>-8</sup>. Only independent SNPs (using  $r^2$ <0.01 in the European 1000 Genomes population) were included. Instrument SNPs for the blood pressure analysis were selected with a similar approach using 249 a published blood pressure GWAS.<sup>36</sup> The outcome summary statistics were those of the single-trait HCM case-control meta-analysis (5,927 cases and 68,359 controls). We also performed a GWAS meta- analysis including data from HCMR and the Canadian HCM cohort (**Supplementary Table 1**) for nHCM (2,491 cases and 27,109 controls) and oHCM (964 cases and 27,163 controls) to use as outcomes. For these stratified analyses, oHCM was defined as HCM in presence of a LV outflow tract gradient ≥30mmHg at rest or during Valsalva/exercise at any time point. All other HCM cases were considered nHCM. Notably, nHCM and oHCM show high genetic correlation (rg=0.87 with standard error, SE=0.13; P=4x10<sup>-11</sup>), suggesting a substantially shared genetic basis.

 Insertions/deletions and palindromic SNPs with intermediate allele frequencies (MAF>0.42) were 258 excluded, and other SNPs in the same locus were included only if P<5x10<sup>-8</sup>. An inverse variance weighted MR model was used as a primary analysis. We used three additional methods as sensitivity analyses: weighted median, weighted mode and MR Egger. Cochran's Q statistics were calculated to investigate heterogeneity between SNP causal effects using IVW. Evidence of directional pleiotropy 262 was also assessed using the MR Egger intercept. Mean F-statistics were calculated to assess the strength of the genetic instruments used. Leave-one-out analyses were also performed to ensure the SNP causal effects are not driven by a particular SNP. The summary results of MR analyses are shown in **Figure 5** and **Supplementary Table 16**, with effect plots shown in **Supplementary Figures 14**

- 266 (contractility) and **Supplementary Figure 16** (blood pressure), and leave-one-out analyses for the
- 267 contractility MR in **Supplementary Figure 15**. The MR effects are shown per unit change (% for
- 268 contractility; mmHg for blood pressure) in **Supplementary Table 16** and **Supplementary Figures 14-**
- **16**, and per SD change in **Figure 5**. OR per SD increase are calculated as follows  $OR = e^{\beta_{MR} \times SD}$ . SDs
- 270 are reported in **Supplementary Table 16** and correspond to those in the current UKB CMR dataset (for
- 271 contractility) and those reported by Evangelou et al<sup>36</sup> in the UK Biobank (for blood pressure).

### **Data availability**

- Data from the Genome Aggregation Database (gnomAD, v.2.1.1) are available at
- https://gnomad.broadinstitute.org. Data from the UKB can be requested from the UKB Access
- Management System (https://bbams.ndph.ox.ac.uk). Data from the GTEx consortium are available at
- 276 the GTEx portal (https://gtexportal.org). Published snRNA-seq data are available at the Broad Single
- Cell Portal (singlecell.broadinstitute.org) and at the Cellxgene tool website
- (https://cellxgene.cziscience.com/collections/e75342a8-0f3b-4ec5-8ee1-245a23e0f7cb/private).
- Other datasets generated during and/or analyzed during the current study can be made available
- upon reasonable request to the corresponding authors. Individual level data sharing is subject to
- restrictions imposed by patient consent and local ethics review boards. Summary statistics of GWAS
- and MTAG will be made available in the GWAS catalog upon publication following peer-review, and
- interactive Manhattan and regional plots will be made available at www.well.ox.ac.uk/hcm.

#### **Acknowledgements**

- This work was supported by funding from the British Heart Foundation (BHF, RG/18/9/33887,
- RE/18/4/34215, FS/15/81/31817); the National Heart, Lung, and Blood Institute (NIH grant
- U01HL117006-01A1); the Wellcome Trust (201543/B/16/Z, 107469/Z/15/Z, 200990/A/16/Z); the
- Wellcome Trust core awards (090532/Z/09/Z, 203141/Z/16/Z); the National Institute for Health
- Research (NIHR) Oxford Biomedical Research Centre; the NIHR Imperial College Biomedical Research
- Centre; NIHR Royal Brompton Cardiovascular Biomedical Research Unit; Sir Jules Thorn Charitable
- Trust [21JTA]; the Medical Research Council (MRC, UK); the Dutch Heart Foundation (CVON 2018-30
- PREDICT2); the Horstingstuit Foundation; the Montreal Heart Institute Foundation; the Philippa and
- Marvin Carsley Cardiology Chair; the Fonds de la Recherche du Québec-Santé (254616, 265449); the
- Canadian Institutes for Health Research (CIHR, 428321). For the purpose of open access, the authors
- have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from
- 296 this submission. The views expressed in this work are those of the authors and not necessarily those of the funders.
- R.T. holds the Canada Research Chair in translational cardiovascular genetics. S.L.Z. received support from BHF Centre of Research Excellence Clinical Research Fellowship (RE/18/4/34215). C.F. received funding from a BHF Clinical Research Training Fellowship (FS/15/81/31817). A.R.H. received support
- from the MRC Doctoral Training Partnership. X.X. is currently a post-doc scientist funded by MRC-

 London Institute of Medical Sciences. R.W. received support from an Amsterdam Cardiovascular Sciences fellowship. M.T. receives support from Monat Foundation. S.J.J. was supported by a Junior Clinical Scientist Fellowship (03-007-2022-0035) from the Dutch Heart Foundation, and by an Amsterdam UMC Doctoral Fellowship. Y.M.P. receives support from the Dutch Heart Foundation (CVON PRIME). B.P.H. is funded by the BHF Intermediate Fellowship (FS/ICRF/21/26019). D.P.O'R. is supported by the MRC (MC\_UP\_1605/13) and BHF (RG/19/6/34387). R.A.d.B. is supported by the Dutch Heart Foundation (2020B005), by the Leducq Foundation (Cure-PLaN), and by the European Research Council (ERC CoG 818715). I.C. receives support from the Dutch Heart Foundation (CVON 2015-12 eDETECT). P.M.M. received funding from the Edmond J. Safra Foundation and Lily Safra and an NIHR Senior Investigator Award, the UK Dementia Research Institute, which receives its funding from UK DRI Ltd., funded by the MRC, Alzheimer's Society, and Alzheimer's Research UK and the Imperial College British Heart Foundation Centre of Excellence. J.-C.T. holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis, and he is also the principal investigator of the Montreal Heart Institute André and France Desmarais hospital cohort funded by the Montreal Heart Institute Foundation. A.G. has received support from the BHF, European Commission [LSHM-CT- 2007-037273, HEALTH-F2-2013- 601456] and TriPartite Immunometabolism Consortium [TrIC]- NovoNordisk Foundation [NNF15CC0018486], BHF-DZHK (SP/19/2/344612). C.R.B. received support from EJP-RD (LQTS-NEXT, ZonMW project 40-46300-98-19009) and the Leducq Foundation (project 17CVD02). HW is member of the Oxford BHF Centre for Research Excellence (RE/13/1/30181). HW and JW are supported by CureHeart, the British Heart Foundation's Big Beat Challenge award (BBC/F/21/220106).

 This research has been conducted in part using the UK Biobank Resource under application numbers 18545 and 47602. This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care), and funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and

 NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal.

#### **Competing Interests**

 R.T. has received research support from Bristol Myers Squibb. A.R.H. is a current employee and stockholder of AstraZeneca. D.P.O'R. has received grants and consultancy fees from Bayer. R.d.B. has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and also has speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche. P.G. receives research funds from Abbott Cardiovascular and Medtronics. C.M.K. received research grants from Cytokinetics and Bristol Myers Squibb. P.M.M. has received consultancy fees from Roche, Biogen, Nodthera and Sangamo Pharmaceuticals and has received research or educational funds from Biogen, Novartis, Merck and Bristol Myers Squibb. J.-C.T. has received research grants from Amarin, AstraZeneca, Ceapro, DalCor, Esperion, Ionis, Novartis, Pfizer and RegenXBio; honoraria from AstraZeneca, DalCor, HLS Therapeutics, Pendopharm and Pfizer; holds minor equity interest in DalCor; and is an author of a patent on pharmacogenomics-guided CETP inhibition. J.S.W. has received research support or consultancy fees from Myokardia, Bristol-Myers Squibb, Pfizer, and Foresite Labs. C.R.B. has consulted for Illumina. H.W. has consulted for Cytokinetics, BridgeBio and BioMarin.

## **References**

- 1 Watkins, H. Time to Think Differently About Sarcomere-Negative Hypertrophic Cardiomyopathy. *Circulation* **143**, 2415-2417, doi:10.1161/CIRCULATIONAHA.121.053527 (2021).
- 2 Harper, A. R. *et al.* Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. *Nat Genet* **53**, 135-142, doi:10.1038/s41588-020- 00764-0 (2021).
- 3 Tadros, R. *et al.* Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nat Genet* **53**, 128-134, doi:10.1038/s41588- 020-00762-2 (2021).
- 4 Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* **44**, 369-375, S361-363, doi:10.1038/ng.2213 (2012).
- 5 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-295, doi:10.1038/ng.3211 (2015).
- 6 Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing heritability for disease from genome-wide association studies. *Am J Hum Genet* **88**, 294-305, doi:10.1016/j.ajhg.2011.02.002 (2011).
- 7 Robinson, P., Griffiths, P. J., Watkins, H. & Redwood, C. S. Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. *Circ Res* **101**, 1266-1273, doi:10.1161/CIRCRESAHA.107.156380 (2007).
- 8 Pickrell, J. K. *et al.* Detection and interpretation of shared genetic influences on 42 human traits. *Nat Genet* **48**, 709-717, doi:10.1038/ng.3570 (2016).
- 9 Aragam, K. G. *et al.* Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery. *Circulation*, doi:10.1161/CIRCULATIONAHA.118.035774 (2018).
- 10 Mountjoy, E. *et al.* An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. *Nat Genet* **53**, 1527-1533, doi:10.1038/s41588-021- 00945-5 (2021).
- 11 Lee, M. A. *et al.* Archvillin anchors in the Z-line of skeletal muscle via the nebulin C-terminus. *Biochem Biophys Res Commun* **374**, 320-324, doi:10.1016/j.bbrc.2008.07.036 (2008).
- 12 Eraslan, G. *et al.* Single-nucleus cross-tissue molecular reference maps toward understanding disease gene function. *Science* **376**, eabl4290, doi:10.1126/science.abl4290 (2022).
- 13 Deo, R. C. *et al.* Prioritizing causal disease genes using unbiased genomic features. *Genome Biol* **15**, 534, doi:10.1186/s13059-014-0534-8 (2014).
- 14 Pirruccello, J. P. *et al.* Deep learning enables genetic analysis of the human thoracic aorta. *Nat Genet* **54**, 40-51, doi:10.1038/s41588-021-00962-4 (2022).
- 15 Hedberg-Oldfors, C. *et al.* Loss of supervillin causes myopathy with myofibrillar disorganization and autophagic vacuoles. *Brain* **143**, 2406-2420, doi:10.1093/brain/awaa206 (2020).
- 16 Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nat Genet* **50**, 229-237, doi:10.1038/s41588-017-0009-4 (2018).
- 17 Bai, W. *et al.* A population-based phenome-wide association study of cardiac and aortic structure and function. *Nat Med* **26**, 1654-1662, doi:10.1038/s41591-020-1009-y (2020).
- 18 Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet* **47**, 1236-1241, doi:10.1038/ng.3406 (2015).
- 19 de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol* **11**, e1004219, doi:10.1371/journal.pcbi.1004219 (2015).
- 20 Reichart, D. *et al.* Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies. *Science* **377**, eabo1984, doi:10.1126/science.abo1984 (2022).
- 21 Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics. *Nat Genet* **54**, 1479-1492, doi:10.1038/s41588- 022-01187-9 (2022).
- 22 Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826, doi:10.1038/s41467-017-01261-5 (2017).
- 23 Chaffin, M. *et al.* Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy. *Nature* **608**, 174-180, doi:10.1038/s41586-022-04817-8 (2022).
- 24 Mizushima, W. *et al.* The novel heart-specific RING finger protein 207 is involved in energy metabolism in cardiomyocytes. *J Mol Cell Cardiol* **100**, 43-53, doi:10.1016/j.yjmcc.2016.09.013 (2016).
- 25 Cattin, M. E. *et al.* Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation. *J Biol Chem* **290**, 26699-26714, doi:10.1074/jbc.M115.678433 (2015).
- 26 Tshori, S. *et al.* Transcription factor MITF regulates cardiac growth and hypertrophy. *J Clin Invest* **116**, 2673-2681, doi:10.1172/JCI27643 (2006).
- 27 Risebro, C. A. *et al.* Prox1 maintains muscle structure and growth in the developing heart. *Development* **136**, 495-505, doi:10.1242/dev.030007 (2009).
- 28 Luo, W. *et al.* TMEM182 interacts with integrin beta 1 and regulates myoblast differentiation and muscle regeneration. *J Cachexia Sarcopenia Muscle* **12**, 1704-1723, doi:10.1002/jcsm.12767 (2021).
- 29 Beca, S. *et al.* Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. *Circ Res* **112**, 289-297, doi:10.1161/CIRCRESAHA.111.300003 (2013).
- 30 Yoshida, M. *et al.* Impaired Ca2+ store functions in skeletal and cardiac muscle cells from sarcalumenin-deficient mice. *J Biol Chem* **280**, 3500-3506, doi:10.1074/jbc.M406618200 (2005).
- 31 Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves association detection. *PLoS Genet* **15**, e1007889, doi:10.1371/journal.pgen.1007889 (2019).
- 32 Shi, X. *et al.* Zebrafish hhatla is involved in cardiac hypertrophy. *J Cell Physiol* **236**, 3700-3709, doi:10.1002/jcp.30106 (2021).
- 33 Green, E. M. *et al.* A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. *Science* **351**, 617-621, doi:10.1126/science.aad3456 (2016).
- 34 Olivotto, I. *et al.* Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* **396**, 759-769, doi:10.1016/S0140-6736(20)31792-X (2020).

- 35 Desai, M. Y. *et al.* Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. *J Am Coll Cardiol* **80**, 95-108, doi:10.1016/j.jacc.2022.04.048 (2022).
- 36 Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet* **50**, 1412-1425, doi:10.1038/s41588-018-0205-x (2018).
- 37 Walsh, R., Offerhaus, J. A., Tadros, R. & Bezzina, C. R. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. *Nat Rev Cardiol* **19**, 151-167, doi:10.1038/s41569-021-00608-2 (2022).
- 38 Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405-424, doi:10.1038/gim.2015.30 (2015).
- 39 Neubauer, S. *et al.* Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. *J Am Coll Cardiol* **74**, 2333-2345, doi:10.1016/j.jacc.2019.08.1057 (2019).
- 40 Magi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics* **11**, 288, doi:10.1186/1471-2105-11-288 (2010).
- 41 Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. *J Am Coll Cardiol* **65**, 1249-1254, doi:10.1016/j.jacc.2015.01.019 (2015).
- 42 Turro, E. *et al.* Whole-genome sequencing of patients with rare diseases in a national health system. *Nature* **583**, 96-102, doi:10.1038/s41586-020-2434-2 (2020).
- 43 Genomics England: The National Genomics Research and Healthcare Knowledgebase v5. (2019). <doi:10.6084/m9.figshare.4530893.v5>.
- 44 McLaren, W. *et al.* Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics* **26**, 2069-2070, doi:10.1093/bioinformatics/btq330 (2010).
- 45 Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434-443, doi:10.1038/s41586-020-2308-7 (2020).
- 46 Petersen, S. E. *et al.* UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson* **18**, 8, doi:10.1186/s12968-016-0227-4 (2016).
- 47 Loh, P. R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet* **47**, 284-290, doi:10.1038/ng.3190 (2015).
- 48 Rehm, H. L. *et al.* ClinGen--the Clinical Genome Resource. *N Engl J Med* **372**, 2235-2242, doi:10.1056/NEJMsr1406261 (2015).
- 49 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191, doi:10.1093/bioinformatics/btq340 (2010).
- 50 Ernst, J. *et al.* Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature* **473**, 43-49, doi:10.1038/nature09906 (2011).
- 51 Roadmap Epigenomics, C. *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317-330, doi:10.1038/nature14248 (2015).
- 52 Fulco, C. P. *et al.* Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbations. *Nat Genet* **51**, 1664-1669, doi:10.1038/s41588-019-0538-0 (2019).
- 53 Nasser, J. *et al.* Genome-wide enhancer maps link risk variants to disease genes. *Nature* **593**, 238- 243, doi:10.1038/s41586-021-03446-x (2021).

- 54 Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat Genet* **47**, 1228-1235, doi:10.1038/ng.3404 (2015).
- 55 Gazal, S. *et al.* Linkage disequilibrium-dependent architecture of human complex traits shows action of negative selection. *Nat Genet* **49**, 1421-1427, doi:10.1038/ng.3954 (2017).
- 56 Gazal, S., Marquez-Luna, C., Finucane, H. K. & Price, A. L. Reconciling S-LDSC and LDAK functional enrichment estimates. *Nat Genet* **51**, 1202-1204, doi:10.1038/s41588-019-0464-1 (2019).
- 57 Ingles, J. *et al.* Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. *Circ Genom Precis Med* **12**, e002460, doi:10.1161/CIRCGEN.119.002460 (2019).
- 58 The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-585, doi:10.1038/ng.2653 (2013).
- 59 Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat Commun* **9**, 1825, doi:10.1038/s41467-018- 03621-1 (2018).
- 60 Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. *Genome Biol* **22**, 49, doi:10.1186/s13059-020-02252-4 (2021).
- 61 Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**, doi:10.7554/eLife.34408 (2018).